UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

LENZ THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter) 001--40532

(Commission File Number)

Delaware

(State or other jurisdiction

84-4867570

(I.R.S. Employer

	Identification No.)		
	92075		
	(Zip code)		
(858) 925-7000			
telephone number, including area code	e)		
Not Applicable former address, if changed since last re	eport)		
aneously satisfy the filing obligation	on of the registrant under any of the following provisions:		
Act (17 CFR 230.425) et (17 CFR 240.14a-12) et the Exchange Act (17 CFR 240) der the Exchange Act (17 CFR 240)			
Trading Symbol(s)	Name of each exchange on which registered		
LENZ	The Nasdaq Stock Market LLC		
ny as defined in Rule 405 of the So	ecurities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of		
	Not Applicable former address, if changed since last reaneously satisfy the filing obligation Act (17 CFR 230.425) act (17 CFR 240.14a-12) der the Exchange Act (17 CFR 24der the Exchange		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financia accounting standards provided pursuant to Section 13(a) of the Exchange Act.								

Item 8.01 Other Events.

LENZ Therapeutics, Inc. ("the Company") is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration's ("FDA") Adverse Event Reporting System ("FAERS") database describing a retinal tear in a patient using VIZZTM (accelidine ophthalmic solution) 1.44%. While FAERS data does not equate to a causal relationship, the Company takes all safety reports seriously and promptly reviewed the case in accordance with our pharmacovigilance procedures.

The patient had a significant history of underlying retinal pathology, including bilateral lattice degeneration, prior peripheral laser treatment, and a previous retinal tear. According to the report, the patient had not undergone a recent peripheral retinal examination before initiating therapy. Several days after starting treatment, but on a non-dosing day, the patient observed a change in vision and was subsequently diagnosed with a retinal tear, and received laser retinopexy. The patient is recovering well.

Independent retina specialists consulted as part of our assessment noted that the patient had multiple pre-existing risk factors that make spontaneous retinal events more likely, and therefore a causal relationship to VIZZ remains uncertain.

Retinal tears occur naturally at an estimated incidence of approximately 25 per 100,000 individuals per year. As VIZZ use continues to expand in real-world settings, isolated retinal events may occur. This initial report, involving a patient with substantial baseline risk, does not alter our current safety expectations for VIZZ.

Going forward, the Company does not expect to provide this level of case detail for each individual report, but felt it was appropriate for this initial instance.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 12, 2025

LENZ THERAPEUTICS, INC.

By: /s/ Evert Schimmelpennink

Name: Evert Schimmelpennink
Title: Chief Executive Officer

(Principal Executive Officer)